Benazepril Combined with Rosiglitazone in Patients with Earlier Period Diabetic Nephropathy

Objective To evaluate the clinical efficacy of benazepril combined with rosiglitazone in patients with earlier period diabetic nephropathy(DN). Methods 64 patients with earlier period DN were randomly allocated to a therapeutic group(n=34) or a control group(n= 30).Patients in the two groups were given the same regimen,such as common treatment,insulin injection and oral benazepril.The therapeutic group were added with oral rosiglitazone 4 mg daily for 3 months.Before and after treatment,levels of systolic blood pressure(SBP),diastolic pressure(DBP),total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol(HDLC),low-density lipoprotein holesterol(LDL-C),creatinine(Scr),urea nitrogen(BUN),high-sensitivity C-reactive protein(us-CRP),fasting blood glucose(FBG),24 h urine protein(Upr),urine beta2-MG were detected respectively.Results In both groups,statistically significant differences in levels of FBG,SBP,DBP,TC,TG,LDLC,urine beta2-MG were observed before and after treatment(P0.05).In the treatment group,as compared with the bacia lever,us-CRP,Scr,Upr were decreased(P0.05),in the control group,they were decreased,but have no statistically differences;FBG,us-CRP,Scr,Upr,urine β2-MG were recorded in the therapeutic group as compared with controls(P0.05). Conclusion Benazepril combined with rosiglitazone in treatment of DN showed better effectiveness in reducing albuminuria and improving renal function than benazepril alone,which suggested that combination of the two drugs can be synergistic against DN development.